-
公开(公告)号：US20240132843A1
公开(公告)日：2024-04-25
申请号：US18547627
申请日：2022-02-23
发明人： John CHO , Kerem Jonatan TUNCEL
IPC分类号： C12N5/0783 , A61K39/00 , C12N9/22 , C12N15/11 , C12N15/90
CPC分类号： C12N5/0637 , A61K39/4611 , C12N9/22 , C12N15/11 , C12N15/907 , A61K2239/26 , C12N2501/2302 , C12N2501/51 , C12N2501/515 , C12N2501/53
摘要： Provided herein are ex vivo methods for expanding regulatory T cells (Tregs), including engineered Tregs, while maintaining their stability and activity. In addition to improving growth and expansion of Tregs, the methods, which can comprise the use of discontinuous stimulation of regulatory T cells (DSORT™), produce Tregs with increased stability and activity.
-
公开(公告)号：US20230065636A1
公开(公告)日：2023-03-02
申请号：US17792472
申请日：2021-01-14
发明人： Hanlan LIU , Robert M. WENSLOW, Jr.
IPC分类号： C07D487/04 , A61K9/10 , A61K47/38 , A61K47/32 , A61K9/16
摘要： Pharmaceutical formulations comprising substituted pyrazolopyrimidines are disclosed herein. Also disclosed are amorphous solid dispersions comprising substituted pyrazolopyrimidines, processes for preparing these amorphous solid dispersions, pharmaceutical compositions comprising such dispersions, and methods of use thereof.
-
公开(公告)号：US11261428B2
公开(公告)日：2022-03-01
申请号：US16354100
申请日：2019-03-14
发明人： Micah Benson , Jason Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael Schlabach , Noah Tubo , James Martin Kaberna, II
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N15/11 , C12N15/113 , C12N9/22 , A61K38/00 , A61K39/00
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20190284529A1
公开(公告)日：2019-09-19
申请号：US16354098
申请日：2019-03-14
发明人： Micah Benson , Jason Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael Schlabach , Noah Tubo
IPC分类号： C12N5/0783 , C07K14/725 , A61K35/17 , A61P35/00 , C12N9/22 , C12N15/113 , C12N15/11 , C07K14/705 , C07K16/28 , C07K16/32 , A61P35/04
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US12084682B2
公开(公告)日：2024-09-10
申请号：US18065580
申请日：2022-12-13
发明人： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo , James Martin Kaberna, II
IPC分类号： C12N5/0783 , A61K35/17 , A61K38/00 , A61K39/00 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N9/22 , C12N15/11 , C12N15/113
CPC分类号： C12N5/0636 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K16/2863 , C07K16/32 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/1135 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/622 , C07K2319/30 , C12N2310/122 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12N2800/80
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20230340411A1
公开(公告)日：2023-10-26
申请号：US18065580
申请日：2022-12-13
发明人： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo , James Martin Kaberna, II
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , A61P35/04 , C12N9/22 , C12N15/113 , C12N15/11 , C07K16/28 , C07K16/32 , C07K14/705 , C07K14/725
CPC分类号： C12N5/0636 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K16/2863 , C07K16/32 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/1135 , A61K38/00
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20230203046A1
公开(公告)日：2023-06-29
申请号：US18045770
申请日：2022-10-11
IPC分类号： C07D487/04 , A61P35/00 , C12Q1/6886
CPC分类号： C07D487/04 , A61P35/00 , C12Q1/6886 , C12Q2600/156
摘要： The present disclosure provides compounds having Formula I:
and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5′, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.-
公开(公告)号：US20220315921A1
公开(公告)日：2022-10-06
申请号：US17836793
申请日：2022-06-09
发明人： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo
IPC分类号： C12N15/11 , A61P35/00 , A61P35/02 , A61P35/04 , C12N9/22 , C12N15/113 , C12N5/0783 , C07K16/28 , C07K16/32 , C07K14/725 , C07K14/705 , A61K35/17
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US11459544B2
公开(公告)日：2022-10-04
申请号：US17707789
申请日：2022-03-29
发明人： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo , James Martin Kaberna, II
IPC分类号： C12N5/0783 , C12N15/113 , C12N9/22 , C12N15/11 , C07K16/32 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/725 , C07K16/28 , A61K39/00 , A61K38/00
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20210388349A1
公开(公告)日：2021-12-16
申请号：US17357400
申请日：2021-06-24
发明人： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo
IPC分类号： C12N15/11 , A61P35/00 , A61P35/02 , A61P35/04 , C07K14/725 , C07K14/705 , C07K16/28 , C07K16/32 , C12N5/0783 , C12N9/22 , C12N15/113 , A61K35/17
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.024 秒)
